Prostatic Artery Embolization Market Growth Accelerated By Rising Awareness About Minimally Invasive Treatment Options

Prostatic Artery Embolization Market

Prostatic artery embolization (PAE) involves minimal steps to block the blood flow to an enlarged prostate gland using interventional radiology techniques. It is a minimally invasive procedure that helps reduce prostate size and improve symptoms of benign prostatic hyperplasia (BPH) such as urinary difficulties. The procedure provides long-lasting relief from BPH symptoms and preserves sexual function.

The global prostatic artery embolization market is estimated to be valued at US$ 235 Mn in 2023 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

The rising awareness about minimally invasive treatment options for BPH is one of the key factors fueling the growth of the prostatic artery embolization market. PAE is a minimally invasive alternative to TURP (transurethral resection of the prostate) which is associated with risks such as retrograde ejaculation and erectile dysfunction. PAE offers advantages such as quicker recovery with little to no side effects. It helps reduce the size of the enlarged prostate gland and relives urinary difficulties without any surgical incision. As awareness increases about PAE's benefits over other treatment options, more patients are likely to opt for it, thereby driving the market growth over the forecast period.
Segment Analysis
The global prostatic artery embolization market is dominated by peripheral embolization sub segment. This is because peripheral prostatic artery embolization allows targeted containment of blood flow to benign prostatic hyperplasia while minimizing damage to surrounding healthy tissue. This minimally invasive procedure reduces post procedure complications and pain with faster recovery time as compared to other treatment options.

Key Takeaways

The global Prostatic Artery Embolization Market Share is estimated to be valued at US$ 235 Mn in 2023 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030.

The global prostatic artery embolization market is expected to witness high growth. Regional analysis: North America region currently dominates the market owing to rising geriatric population, growing adoption of minimally invasive procedures and favorable reimbursement policies in countries like US and Canada. The region is expected to maintain its dominating position during the forecast period from 2023 to 2030.

Key players related content comprises: Key players operating in the prostatic artery embolization market are Amgen Inc., Samsung Bioepis Co., Ltd., Sandoz International GmbH (Novartis AG), Mylan N.V., Boehringer Ingelheim International GmbH, Pfizer Inc., Fresenius Kabi AG, Coherus BioSciences, Inc., Biogen Inc., AbbVie Inc., Celltrion Inc., Amneal Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Viatris Inc.

For more insights, read- https://www.ukwebwire.com/prostatic-artery-embolization-market-trends-size-and-share-analysis/